ABUS vs CTAS · P/E 5.4, rev $6.2M vs P/E 51, rev $10.34B
Arbutus Biopharma Corp (ABUS) versus Cintas Corporation (CTAS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Not investment advice. Open the ABUS and CTAS stock pages for the full models.
Not investment advice.